Last updated: 2026-10-19 21:26:00. Prices reflect the latest after-hours trading data. Stock price data is sourced from Massive.
Annexon, Inc. (ANNX) operates in the PHARMACEUTICAL PREPARATIONS sector and is listed on NASDAQ. The stock is currently priced at $4.03, with a market capitalization of $646.46M and a P/E ratio of --. Over the past 52 weeks, its price has ranged from $2.54 to $7.18. This page covers its latest market performance, valuation, price trends and company information.
$646.46M | |
$3.65 | |
$38.01 | |
$1.29 | |
$3.41 | |
5.63M | |
2.91M | |
-- | |
$7.18 | |
$2.54 | |
-- | |
-- |
Annexon, Inc. (ANNX) is trading at $4.05 in after-hours trading as of 2026-10-19 21:25:00, up 18.77% ($0.64) from the regular-session close of $3.41.
After-hours trading shows how investors are pricing ANNX after the regular session closes. The current after-hours price is above the regular-session close, indicating positive after-hours sentiment.
Over the past seven days, Annexon, Inc. (ANNX) moved from $4.00 to $4.03, representing a gain of 0.63% ($0.03).
The stock traded between $3.36 and $4.14 during the period. The latest price is near the upper end of the 7-day range, indicating moderate upward.
The average daily volume was 3.27 million shares, down versus the previous seven-day period, indicating lower trading activity.
Position in Range: 32.0%
ANNX is currently trading at $4.03, placing it 32.0% of the way from its 52-week low of $2.54 to its 52-week high of $7.18. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
Annexon Inc is a clinical-stage biopharmaceutical company developing a pipeline of novel therapies for patients with classical complement-mediated disorders of the body, brain, and eye. Its pipeline is based on its platform technology addressing well-researched classical complement-mediated autoimmune and neurodegenerative disease processes, both of which are triggered by aberrant activation of C1q. Its pipeline of product candidates is designed to block the activity of C1q and the entire classical complement pathway in a broad set of complement-mediated diseases. Its product candidates are ANX005, for autoimmune & neurodegenerative disorders; ANX007, for neurodegenerative ophthalmic disorders; ANX1502, for Oral small molecule; and ANX009, for systemic autoimmune diseases.
| Industry | PHARMACEUTICAL PREPARATIONS |
| Employees | 92 |
| Exchange | NASDAQ |
| Company Website |
Eligible investors can buy real shares of Annexon, Inc. (ANNX) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.